Publication
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Authors not recorded
Lancet Oncol2020PMID 32203698PMC8461541stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerCholangiolocellular Small Duct Intrahepatic Cholangiocarcinomacivic_curation1.00
- drugPemigatinibcivic_curation1.00
- geneFGFR2civic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 32203698
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR2 Fusion + FGFR2 Fusion1 | ||||||||
| Pemigatinib | Cholangiolocellular Small Duct Intrahepatic CholangiocarcinomaALIAS | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID8173In a multicentre, open-label, single-arm, phase 2 study (FIGHT-202), patients with disease progression following at least one previous treatment received a starting dose of 13·5 mg oral pemigatinib on… (full text at CIViC) PMID 32203698 · Abou-Alfa et al., 2020 · Open in CIViC | civic |